Journal of Hepatology
Volume 51, Issue 4 , Pages 640-646, October 2009

Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B☆

  • Maria Buti

      Affiliations

    • Servicio de Hepatologı´a, Hospital Vall d’Hebrón and Ciber-ehd del Instituto Carlos III, Barcelona, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 93 2746140; fax: +34 93 2746068.
    • ,
  • Max Brosa

      Affiliations

    • Oblikue Consulting, Barcelona, Spain
    • ,
  • Miguel A. Casado

      Affiliations

    • Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain
    • ,
  • Magdalena Rueda

      Affiliations

    • Gilead Sciences Inc., Madrid, Spain
    • ,
  • Rafael Esteban

      Affiliations

    • Servicio de Hepatologı´a, Hospital Vall d’Hebrón and Ciber-ehd del Instituto Carlos III, Barcelona, Spain

Received 19 January 2009; received in revised form 16 March 2009; accepted 1 April 2009. published online 20 May 2009.

Associate Editor: R.P. Perrillo

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This study was supported in part by a research grant from Gilead Sciences. The authors had independence from the funding company in study design, analysis and interpretation of the data, report writing, and publication, regardless of the results. M. Brosa is an employee of Oblikue Consulting; M.C. is an employee of Pharmaeconomics & Outcomes Research Iberia; M.R. is an employee of Gilead Sciences Inc.; M. Buti, M. Brosa and R. Esteban are on the Advisory board for Gilead, Novartis. Speaker: Gilead, Novartis, Bristol-Myers Squibb and Schering-Plough.

PII: S0168-8278(09)00322-5

doi:10.1016/j.jhep.2009.04.013

Refers to article:

  • Cost-effectiveness of oral treatments for chronic hepatitis B , 06 August 2009

    Geoffrey M. Dusheiko
    Journal of Hepatology October 2009 (Vol. 51, Issue 4, Pages 623-625)

Journal of Hepatology
Volume 51, Issue 4 , Pages 640-646, October 2009

Article Tools

* Image Usage & Resolution